Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26466017 | 0.83 | ALDH1A1 (0.35) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL26466014 | 0.83 | ALDH1A1 (0.35) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL26096510 | 0.79 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL30070945 | 0.76 | CYP3A4 (0.33) | ALDH1A1TP53CYP3A4SMN1; SMN2 | |
| SCHEMBL26465995 | 0.75 | — | — | |
| SCHEMBL3828085 | 0.64 | TDP1 (0.49) | ALDH1A1ALOX15 | |
| SCHEMBL26465986 | 0.64 | DUT (0.34) | — | |
| SCHEMBL28353944 | 0.62 | IDO1 (0.45) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL11946164 | 0.62 | CHRM3 (0.39) | — | |
| SCHEMBL1798199 | 0.62 | OPRM1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | ALDH1A1 383/4885TP53 4159/4885CYP3A4 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.